Ritonavir/Nirmatrelvir
Top in Healio: COVID-19 rebound; how PCPs can combat suicide rates
Two analyses found antiviral drugs like Paxlovid do not elevate the risk for COVID-19 rebound, contrary to previous research.
Top in ID: Paxlovid unlikely contributes to COVID-19 rebound; a roundup of 2023 guidelines
Two separate analyses of studies and trials suggest that COVID-19 rebound is not linked to Paxlovid or other antiviral drugs.
'Mysterious and sometimes debilitating': The complexity of managing long COVID
Long COVID can be difficult for primary care physicians to manage, but they are in a unique position to provide the best care for the condition, according to experts.
COVID-19 rebounds in one in five Paxlovid users
About 20% of patients with COVID-19 experienced virologic rebound after receiving Paxlovid, according to an observational study published in Annals of Internal Medicine.
Paxlovid, Lagevrio reduce mortality risk in patients with COVID-19
As an outpatient treatment for COVID-19, the antivirals Paxlovid and Lagevrio were both associated with reduced mortality rates, but only Paxlovid was associated with a reduction in hospitalization, data show.
VIDEO: Three new treatments relevant to primary care
SAN DIEGO — Gerald W. Smetana, MD, MACP, provided an update on three new treatments that are important to primary care physicians.
Antiviral associated with 26% reduced risk for long COVID
The antiviral nirmatrelvir, which is part of Paxlovid, was linked to a significant reduction in the risk for long COVID and post-acute death in patients with at least one risk factor for severe illness, according to researchers.
Why is it important to maintain access to Paxlovid?
The public health and national emergencies related to the COVID-19 pandemic are set to end on May 11.
Should the FDA approve Paxlovid before the emergencies end?
The public health and national emergencies related to the COVID-19 pandemic are set to end on May 11.
Paxlovid reduces hospitalization, death risk in vaccinated patients
Real-world data on Paxlovid showed it was associated with a reduced risk for hospitalization or death in outpatients with early COVID-19 “in the context of high vaccination prevalence and an intense omicron epidemic,” researchers reported.